Dr. Jiyang Xue | Targeted Cancer Immunotherapy | Research Excellence Award

Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine | China

Dr. Xue Jiyang is a Deputy Chief Pharmacist at Shanghai First Maternity and Infant Hospital and a Ph.D. candidate at Tongji University, specializing in clinical pharmacy, pharmacokinetics, and nanomedicine. Dr. Xue research integrates pharmaceutical sciences with maternal–fetal medicine, oncology, and translational drug delivery. A key focus of Dr. Xue’s work is pharmacokinetic behavior and drug safety during pregnancy, addressing critical gaps in evidence-based medication use for pregnant populations. Dr. Xue has led multiple competitive research projects, including two grants from the National Natural Science Foundation of China, investigating innovative nanocomposite and nanodrug delivery systems targeting the CXCL12/CXCR4 and PD-1/PD-L1 signaling pathways to remodel the immunosuppressive tumor microenvironment in ovarian cancer. Dr. Xue’s studies employ advanced nanotechnology, tumor immunology, and molecular pharmacology to enhance therapeutic efficacy and overcome drug resistance. In parallel, Dr. Xue has conducted pioneering research on environmental exposure during pregnancy, including the impact of maternal microplastic exposure on fetal growth and development, providing important insights into maternal–fetal health risks. Dr. Xue has published more than 10 SCI-indexed papers in high-impact journals such as Redox Biology, Science of the Total Environment, International Journal of Nanomedicine, and Small. Dr. Xue’s contributions have been recognized through prestigious honors and youth talent programs in Shanghai, reflecting Dr. Xue’s growing influence in clinical and translational pharmaceutical research.

View Scopus Profile

Featured Publications